Claims for Patent: 7,608,683

Summary for Patent: 7,608,683

Title:	Stress proteins and peptides and methods of use thereof
Abstract:	Provided are HLA pan DR-binding peptides and methods of using such peptides to modulate, block, or inhibit immune responses to effect treatment of immune-mediated diseases and conditions, such as inflammatory and autoimmune diseases, cancer, and microbial infections. These peptides and methods are also useful diagnostically to screen peptide or peptide analogs that can inhibit the pathogenic immune response or up-regulate an immune response against aberrant or invading cells, to monitor efficacy for therapeutic treatments, and to identify other agents that may be effective to inhibit or otherwise modulate an immune response such as by altering T cell functional phenotype, and even more particularly by modulating the regulatory phenotype of regulatory T cells and/or inducing emergence of T cells with a different functional phenotype.
Inventor(s):	Albani; Salvatore (Encinitas, CA), Prakken; Berent J. (Utrechi, NL)
Assignee:	The Regents of the University of California (Oakland, CA)
Application Number:	11/080,458
Patent Claims:	1. An isolated peptide consisting of the amino acid sequence as set forth in SEQ ID NO: 24. 2. The isolated peptide of claim 1, wherein the peptide is at least about 90% pure by weight. 3. The isolated peptide of claim 1 wherein the peptide contains one or more D-amino acids. 4. The isolated peptide of claim 1 wherein the peptide is covalently linked to an adjuvant. 5. The isolated peptide of claim 4 wherein the adjuvant is selected from the group consisting of keyhole limpet hemocyanin, bovine serum albumin, human serum albumin, and isologous IgG. 6. A pharmaceutical composition comprising the peptide of claim 1 in a pharmaceutically acceptable carrier. 7. A composition comprising a pharmaceutically acceptable carrier and the isolated peptide of claim 4. 8. The composition of claim 7 wherein the peptide binds to a molecule selected from the group consisting of HLADR1, DR4, and DR7. 9. The isolated peptide of claim 1, wherein the peptide is chemically synthesized. 10. The isolated peptide of claim 1, wherein the peptide is glycosylated.

Details for Patent 7,608,683

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942		2020-08-09
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954		2020-08-09
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976		2020-08-09
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	08/15/1978		2020-08-09
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	02/17/1995		2020-08-09
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	06/11/2003		2020-08-09
Csl Behring Llc	ALBUMINAR, ALBUMINAR-20, ALBUMINAR-25, ALBUMINAR-5	albumin (human)	Injection	103955	03/17/2000		2020-08-09